NASDAQ:NURO

NeuroMetrix - NURO Stock Forecast, Price & News

$3.57

+0.22 (+6.57%)

(As of 08/10/2022 12:00 AM ET)

Add

Compare

Today's Range: $3.35
▼
$3.60
50-Day Range: $3.07
▼
$4.36
52-Week Range: $2.70
▼
$19.74

Volume: 72,058 shs
Average Volume: 1.24 million shs
Market Capitalization: $25.45 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About NeuroMetrix (NASDAQ:NURO) Stock

NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

NeuroMetrix Trading Down 10.2 %

Shares of NASDAQ:NURO opened at $3.35 on Wednesday. The stock has a fifty day simple moving average of $3.65 and a 200-day simple moving average of $3.89. NeuroMetrix has a twelve month low of $2.70 and a twelve month high of $19.74. The stock has a market capitalization of $23.89 million, a PE ratio of -5.78 and a beta of 2.60.

NeuroMetrix (NASDAQ:NURO - Get Rating) last announced its earnings results on Thursday, July 21st. The medical device company reported ($0.17) earnings per share for the quarter. The business had revenue of $2.14 million for the quarter. NeuroMetrix had a negative return on equity of 16.02% and a negative net margin of 45.76%.

Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

NURO Stock News Headlines

August 5, 2022 | nasdaq.com

Selling US$799k worth of NeuroMetrix, Inc. (NASDAQ:NURO) stock at high prices would have gotten insiders a handsome reward - Nasdaq

July 22, 2022 | nasdaq.com

DGX Boosts FY22 Outlook, NURO On Watch, PSTV To Present ReSPECT-GBM Data In Sep. - Nasdaq

July 21, 2022 | investing.com

NeuroMetrix Reports Q2 Loss of $0.17 By Investing.com - Investing.com

July 21, 2022 | in.investing.com

NeuroMetrix Reports Q2 Loss of $0.17 By Investing.com - Investing.com India

July 21, 2022 | finance.yahoo.com

NeuroMetrix Reports Q2 2022 Financial Results - Yahoo Finance

July 21, 2022 | au.investing.com

NeuroMetrix Reports Q2 Loss of $0.17 By Investing.com - Investing.com Australia

July 21, 2022 | seekingalpha.com

NeuroMetrix stock dips as Q2 net loss widens, revenue falls Y/Y - Seeking Alpha

July 21, 2022 | globenewswire.com

NeuroMetrix Reports Q2 2022 Financial Results - GlobeNewswire

July 21, 2022 | finance.yahoo.com

NeuroMetrix Reports Q2 2022 Financial Results

July 14, 2022 | benzinga.com

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call - Benzinga

July 14, 2022 | finance.yahoo.com

NeuroMetrix, Inc. Announces Date for Second Quarter 2022 Financial Results Conference Call

July 7, 2022 | streetinsider.com

Form 3 NeuroMetrix, Inc. For: Jul 01 Filed by: Fluegel Bradley M - StreetInsider.com

June 28, 2022 | businesswire.com

The Worldwide Smart Medical Devices Industry is Expected to Reach $122.8 Billion by 2026 - ResearchAndMarkets.com - Business Wire

June 28, 2022 | globenewswire.com

NeuroMetrix Appoints Brad Fluegel to its Board of Directors - GlobeNewswire

June 28, 2022 | finance.yahoo.com

NeuroMetrix Appoints Brad Fluegel to its Board of Directors

May 22, 2022 | nasdaq.com

Pre-market Movers: ROST, EVEX, TIGO, CGEN, PANW… - Nasdaq

May 20, 2022 | marketwatch.com

NeuroMetrix Gets FDA Approval to Market Quell Neuromodulation Device - MarketWatch

May 20, 2022 | benzinga.com

Short Volatility Alert: NeuroMetrix - Benzinga - Benzinga

May 20, 2022 | finance.yahoo.com

NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia - Yahoo Finance

May 20, 2022 | streetinsider.com

Hot Penny Stocks to Watch Right Now? 3 For Your List in May - StreetInsider.com

May 19, 2022 | nasdaq.com

Health Care Sector Update for 05/19/2022: NURO,ENTA,CALT,SIGA - Nasdaq

May 19, 2022 | marketwatch.com

NeuroMetrix Shares Jump 33% After FDA Market Approval for Quell Device - MarketWatch

May 19, 2022 | uk.investing.com

US shares lower at close of trade; Dow Jones Industrial Average down 0.75% By Investing.com - Investing.com UK

May 19, 2022 | benzinga.com

NeuroMetrix shares are trading higher after the company announced the FDA has granted De Novo authorizati - Benzinga

May 19, 2022 | benzinga.com

Mid-Afternoon Market Update: Dow Falls 150 Points; NeuroMetrix Shares Spike Higher - Benzinga - Benzinga

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive NURO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroMetrix and its competitors with MarketBeat's FREE daily newsletter.

NURO Company Calendar

Last Earnings: 7/21/2022
Today: 8/10/2022
Next Earnings (Estimated): 10/20/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Surgical & medical instruments
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:NURO
CUSIP: N/A
CIK: 1289850
Web: www.neurometrix.com
Phone: (781) 890-9989
Fax: 302-636-5454
Employees: 23
Year Founded: 1996

Profitability

EPS (Most Recent Fiscal Year): ($0.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-2,280,000.00
Net Margins: -45.76%
Pretax Margin: -45.75%
Return on Equity: -16.02%
Return on Assets: -14.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.51
Quick Ratio: 14.96

Sales & Book Value

Annual Sales: $8.25 million
Price / Sales: 3.09
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.48 per share
Price / Book: 1.03

Miscellaneous

Outstanding Shares: 7,130,000
Free Float: 6,631,000
Market Cap: $25.45 million
Optionable: Not Optionable
Beta: 2.60

Social Links

Key Executives

Dr. Shai N. Gozani M.D. (Age 57)
Ph.D., Founder, Chairman, CEO, Pres & Sec.
Comp: $557.66k
Mr. Thomas T. Higgins (Age 70)
Sr. VP, CFO & Treasurer
Comp: $414.38k
Dr. Xuan Kong Ph.D.
Chief Data Scientist
Ms. Susan M. Bell R.N.
Sr. VP of Population Health & Value Based Care

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

NURO Stock - Frequently Asked Questions

How have NURO shares performed in 2022?: NeuroMetrix's stock was trading at $5.02 at the beginning of 2022. Since then, NURO shares have decreased by 29.9% and is now trading at $3.52.
View the best growth stocks for 2022 here.
When is NeuroMetrix's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 20th 2022.
View our NURO earnings forecast.
How were NeuroMetrix's earnings last quarter?: NeuroMetrix, Inc. (NASDAQ:NURO) posted its earnings results on Thursday, July, 21st. The medical device company reported ($0.17) EPS for the quarter. The medical device company earned $2.14 million during the quarter. NeuroMetrix had a negative trailing twelve-month return on equity of 16.02% and a negative net margin of 45.76%.
When did NeuroMetrix's stock split?: Shares of NeuroMetrix reverse split before market open on Friday, May 12th 2017. The 1-8 reverse split was announced on Thursday, May 11th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, May 11th 2017. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.
What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?: 10 employees have rated NeuroMetrix Chief Executive Officer Shai N. Gozani on Glassdoor.com. Shai N. Gozani has an approval rating of 57% among the company's employees. This puts Shai N. Gozani in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeuroMetrix own?: Based on aggregate information from My MarketBeat watchlists, some companies that other NeuroMetrix investors own include Merit Medical Systems (MMSI), Palatin Technologies (PTN), Citigroup (C), Salesforce (CRM), Nokia Oyj (NOK), Ampio Pharmaceuticals (AMPE), ReWalk Robotics (RWLK), Aurora Cannabis (ACB), Advanced Micro Devices (AMD) and Vaxart (VXRT).
What is NeuroMetrix's stock symbol?: NeuroMetrix trades on the NASDAQ under the ticker symbol "NURO."
How do I buy shares of NeuroMetrix?: Shares of NURO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is NeuroMetrix's stock price today?: One share of NURO stock can currently be purchased for approximately $3.52.
How much money does NeuroMetrix make?: NeuroMetrix (NASDAQ:NURO) has a market capitalization of $25.10 million and generates $8.25 million in revenue each year. The medical device company earns $-2,280,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis.
When was NeuroMetrix founded?: NeuroMetrix was founded in 1996.
How can I contact NeuroMetrix?: NeuroMetrix's mailing address is 4B GILL STREET WOBURN, MASSACHUSETTS MA, 01801. The official website for the company is www.neurometrix.com. The medical device company can be reached via phone at (781) 890-9989, via email at neurometrix.ir@neurometrix.com, or via fax at 302-636-5454.

This page (NASDAQ:NURO) was last updated on 8/11/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

NeuroMetrix - NURO Stock Forecast, Price & News

About NeuroMetrix (NASDAQ:NURO) Stock

NeuroMetrix Trading Down 10.2 %

NURO Stock News Headlines

NURO Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

NURO Stock - Frequently Asked Questions

How have NURO shares performed in 2022?

When is NeuroMetrix's next earnings date?

How were NeuroMetrix's earnings last quarter?

When did NeuroMetrix's stock split?

What is Shai N. Gozani's approval rating as NeuroMetrix's CEO?

What other stocks do shareholders of NeuroMetrix own?

What is NeuroMetrix's stock symbol?

How do I buy shares of NeuroMetrix?

What is NeuroMetrix's stock price today?

How much money does NeuroMetrix make?

When was NeuroMetrix founded?

How can I contact NeuroMetrix?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources